During the last session, Cardiol Therapeutics Inc (NASDAQ:CRDL)’s traded shares were 0.55 million, with the beta value of the company hitting 0.90. At the end of the trading day, the stock’s price was $0.96, reflecting an intraday loss of -3.38% or -$0.03. The company’s market capitalization is $78.34M, and the average intraday trading volume over the past 10 days was 0.23 million shares, and the average trade volume was 255.55K shares over the past three months.
Cardiol Therapeutics Inc (CRDL) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. CRDL has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 0.
Cardiol Therapeutics Inc (NASDAQ:CRDL) trade information
Cardiol Therapeutics Inc (CRDL) registered a -3.38% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -3.38% in intraday trading to $0.96, hitting a weekly high. The stock’s 5-day price performance is -14.29%, and it has moved by -18.64% in 30 days. Based on these gigs, the overall price performance for the year is -47.25%. The short interest in Cardiol Therapeutics Inc (NASDAQ:CRDL) is 1.76 million shares and it means that shorts have 6.24 day(s) to cover.
The consensus price target of analysts on Wall Street is $8, which implies an increase of 88.0% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $8 and $8 respectively. As a result, CRDL is trading at a discount of -733.33% off the target high and -733.33% off the low.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 16.52%. While earnings are projected to return -28.74% in 2025, the next five years will return -6.27% per annum.
CRDL Dividends
Cardiol Therapeutics Inc is due to release its next quarterly earnings on 2024-Nov-13. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Cardiol Therapeutics Inc (NASDAQ:CRDL)’s Major holders
Cardiol Therapeutics Inc insiders own 4.00% of total outstanding shares while institutional holders control 12.19%, with the float percentage being 12.69%. TEJARA CAPITAL LTD is the largest shareholder of the company, while 52.0 institutions own stock in it. As of 2024-06-30, the company held over 1.72 million shares (or 2.505% of all shares), a total value of $3.48 million in shares.
The next largest institutional holding, with 1.47 million shares, is of ADVISORSHARES INVESTMENTS LLC’s that is approximately 2.1337% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $2.93 million.
Also, the Mutual Funds coming in first place with the largest holdings of Cardiol Therapeutics Inc (CRDL) shares are AdvisorShares Trust-AdvisorShares Pure Cannabis ETF and Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund . Data provided on Feb 28, 2025 indicates that AdvisorShares Trust-AdvisorShares Pure Cannabis ETF owns about 882.49 shares. This amounts to just over 1.07 percent of the company’s overall shares, with a $0.85 million market value. The same data shows that the other fund manager holds slightly less at 52.44, or about 0.06% of the stock, which is worth about $50337.0.
